Sunday, June 21, 2015 8:53:06 AM
Brean Capital analyst Difei Yang reiterated a Buy rating and boosted its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $31.00 (from $25.00) on high likilihood of Glatopa being the only generic Copaxone on market for extended period of time.
"Due to an earlier-than-expected launch (June vs. our estimation of September, 2015) coupled with the expected favorable competitive market condition, i.e., less price discount, more market share, we are significantly revising our EPS estimates up," Yang commented. "As a result, our price target increases from $25 to $31."
http://www.streetinsider.com/Analyst+Comments/Momenta+Pharmaceuticals+(MNTA)+PT+Raised+to+$31+at+Brean+Capital/10665045.html
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM